Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
TACR1 6869 CHEMBL319118 CHEMBL319118 DrugBank
TACR1 6869 CHEMBL38763 CHEMBL38763 DrugBank
TACR1 6869 NEUROKININ B CHEMBL437797 agonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL1885865 CHEMBL1885865 agonist GuideToPharmacologyInteractions
TACR1 6869 NALOXONE CHEMBL80 antagonist GuideToPharmacologyInteractions
TACR1 6869 SAREDUTANT CHEMBL308148 antagonist GuideToPharmacologyInteractions
TACR1 6869 SERLOPITANT CHEMBL447955 antagonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL339486 CHEMBL339486 antagonist GuideToPharmacologyInteractions
TACR1 6869 VESTIPITANT CHEMBL522987 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
TACR1 6869 VOFOPITANT CHEMBL522302 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
TACR1 6869 APREPITANT CHEMBL1471 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17643344, 11752352, 15121485, 12590540, 12784346, 12227806
TACR1 6869 ELEDOISIN CHEMBL373569 agonist GuideToPharmacologyInteractions
TACR1 6869 NEUROKININ A CHEMBL217406 agonist GuideToPharmacologyInteractions
TACR1 6869 PHYSALAEMIN CHEMBL2370372 agonist GuideToPharmacologyInteractions
TACR1 6869 BEFETUPITANT CHEMBL204694 antagonist GuideToPharmacologyInteractions
TACR1 6869 CASOPITANT CHEMBL1672054 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
TACR1 6869 LANEPITANT CHEMBL42407 antagonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL131171 CHEMBL131171 antagonist GuideToPharmacologyInteractions
TACR1 6869 MITOMYCIN CHEMBL105 antagonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL129683 CHEMBL129683 antagonist GuideToPharmacologyInteractions
TACR1 6869 VAPREOTIDE CHEMBL2103975 antagonist TEND, DrugBank 11752352, 7556407
TACR1 6869 NETUPITANT CHEMBL206253 antagonist GuideToPharmacologyInteractions, DrugBank 25687374
TACR1 6869 KASSININ CHEMBL436706 agonist GuideToPharmacologyInteractions
TACR1 6869 FOSAPREPITANT CHEMBL1199324 antagonist GuideToPharmacologyInteractions
TACR1 6869 ROLAPITANT CHEMBL3707331 antagonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL1965818 CHEMBL1965818 DrugBank
TACR1 6869 SUBSTANCE P CHEMBL235363 agonist GuideToPharmacologyInteractions
TACR1 6869 ANASTROZOLE CHEMBL1399 antagonist GuideToPharmacologyInteractions
TACR1 6869 EZLOPITANT CHEMBL515966 antagonist GuideToPharmacologyInteractions
TACR1 6869 CHEMBL417572 CHEMBL417572 antagonist GuideToPharmacologyInteractions
TACR1 6869 NOLPITANTIUM CHEMBL1178725 antagonist GuideToPharmacologyInteractions
TACR1 6869 OSANETANT CHEMBL346178 antagonist GuideToPharmacologyInteractions
TACR1 6869 HYDROCORTISONE CHEMBL389621 antagonist GuideToPharmacologyInteractions
TACR1 6869 TRADIPITANT CHEMBL3544984 antagonist GuideToPharmacologyInteractions
TACR1 6869 VASOPRESSIN CHEMBL373742 NCI 18195491

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
TACR1 rs2160652 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele G is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714224
TACR1 rs3771836 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele G is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714238
TACR1 rs2111375 AA granisetron efficacy no Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient. Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG. 29177570 1449170319
TACR1 rs6715729 GG granisetron efficacy no Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient. Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AG. 29177570 1449170332
TACR1 rs12475818 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele G is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714231
TACR1 rs10191107 A opioids dosage no Variant had no significant association with opioid dose in the development sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714246
TACR1 rs12713837 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714253
TACR1 rs6725334 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714260
TACR1 rs2024512 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714267
TACR1 rs881 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. It has been assumed based on the allele frequencies given in the paper that the reported alleles are on the negative strand, as a result, please note that the alleles have been complemented to the positive strand. Allele G is not associated with dose of opioids in people with Pain as compared to allele C. 21398039 1449714203
TACR1 rs4439987 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714210
TACR1 rs6546952 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714217